Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations
dc.contributor.author | Lasa Elgarresta, Jaione | |
dc.contributor.author | Mosqueira Martín, Laura | |
dc.contributor.author | Naldaiz Gastesi, Neia | |
dc.contributor.author | Sáenz Peña, Amets | |
dc.contributor.author | López de Munain Arregui, Adolfo José | |
dc.contributor.author | Vallejo Illarramendi, Ainara ![]() | |
dc.date.accessioned | 2020-01-10T11:47:12Z | |
dc.date.available | 2020-01-10T11:47:12Z | |
dc.date.issued | 2019-09-02 | |
dc.identifier.citation | International Journal Of Molecular Sciences 20(18) : (2019) // Article ID 4548 | es_ES |
dc.identifier.issn | 1422-0067 | |
dc.identifier.uri | http://hdl.handle.net/10810/37572 | |
dc.description.abstract | Limb-girdle muscular dystrophy recessive 1 (LGMDR1), previously known as LGMD2A, is a rare disease caused by mutations in the CAPN3 gene. It is characterized by progressive weakness of shoulder, pelvic, and proximal limb muscles that usually appears in children and young adults and results in loss of ambulation within 20 years after disease onset in most patients. The pathophysiological mechanisms involved in LGMDR1 remain mostly unknown, and to date, there is no effective treatment for this disease. Here, we review clinical and experimental evidence suggesting that dysregulation of Ca2+ homeostasis in the skeletal muscle is a significant underlying event in this muscular dystrophy. We also review and discuss specific clinical features of LGMDR1, CAPN3 functions, novel putative targets for therapeutic strategies, and current approaches aiming to treat LGMDR1. These novel approaches may be clinically relevant not only for LGMDR1 but also for other muscular dystrophies with secondary calpainopathy or with abnormal Ca2+ homeostasis, such as LGMD2B/LGMDR2 or sporadic inclusion body myositis. | es_ES |
dc.description.sponsorship | This research was funded by Instituto de Salud Carlos III, co-funded by European Regional Development Fund/European Social Fund, "Investing in your future" (A.V.-I., PI17/00676; A.L.d.M., PI17/01841); the Basque Government (A.V.-I., 2016111091) and Diputacion Foral de Gipuzkoa (A.V.-I., 2018-000117-01-B and 2019-00362-01-B). A.V.-I. holds a Ramon y Cajal contract funded by the Spanish Ministry of Economy and Competitiveness, and J.L.-E. holds a PhD fellowship from the Basque Government. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | calpain 3 | es_ES |
dc.subject | calcium | es_ES |
dc.subject | LGMD2A | es_ES |
dc.subject | LGMDR1 | es_ES |
dc.subject | muscular dystrophies | es_ES |
dc.subject | calpainopathy | es_ES |
dc.subject | NF-kappa B | es_ES |
dc.subject | permeability transition pore | es_ES |
dc.subject | muscle-specific calpain | es_ES |
dc.subject | skeletal-muscle | es_ES |
dc.subject | oxidative stress | es_ES |
dc.subject | in-vivo | es_ES |
dc.subject | sarcoplasmic-reticulum | es_ES |
dc.subject | mitochondrial activity | es_ES |
dc.subject | proteolytic activity | es_ES |
dc.subject | genetic isolate | es_ES |
dc.title | Calcium Mechanisms in Limb-Girdle Muscular Dystrophy with CAPN3 Mutations | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Attribution 4.0 International (CC BY 4.0) | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.mdpi.com/1422-0067/20/18/4548 | es_ES |
dc.identifier.doi | 10.3390/ijms20184548 | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoes | Pediatría | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
dc.departamentoeu | Pediatria | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Attribution 4.0 International (CC BY 4.0)